Savara Inc. (NASDAQ:SVRA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Savara Inc. (NASDAQ:SVRA) have been assigned a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $9.1250.

A number of equities analysts have issued reports on SVRA shares. Guggenheim reaffirmed a “buy” rating on shares of Savara in a research note on Tuesday, December 23rd. Oppenheimer set a $10.00 target price on Savara in a research note on Tuesday, December 23rd. HC Wainwright lifted their target price on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, December 23rd. Citizens Jmp cut their price target on shares of Savara from $11.00 to $10.00 and set a “market outperform” rating for the company in a report on Thursday, November 13th. Finally, Wells Fargo & Company lifted their price objective on shares of Savara from $7.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday, December 18th.

Savara Stock Performance

Shares of SVRA opened at $5.36 on Thursday. The firm has a market capitalization of $1.09 billion, a PE ratio of -10.11 and a beta of 0.34. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.32. The firm has a 50-day moving average price of $6.05 and a 200 day moving average price of $4.43. Savara has a 52-week low of $1.89 and a 52-week high of $7.01.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). On average, sell-side analysts anticipate that Savara will post -0.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Prudential Financial Inc. bought a new stake in shares of Savara during the 2nd quarter worth $30,000. BNP Paribas Financial Markets lifted its holdings in shares of Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after purchasing an additional 4,626 shares during the last quarter. May Hill Capital LLC purchased a new stake in shares of Savara during the second quarter valued at $32,000. Brevan Howard Capital Management LP acquired a new position in shares of Savara in the 2nd quarter valued at $33,000. Finally, Russell Investments Group Ltd. increased its stake in Savara by 930.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after purchasing an additional 9,463 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.